Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160688 | 1.00 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL12205813 | 0.84 | CYP19A1 (0.65) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL15014123 | 0.79 | CYP19A1 (0.76) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL13780823 | 0.78 | CYP19A1 (0.54) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL13780523 | 0.76 | ALDH1A1 (0.58) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL2641384 | 0.76 | CYP19A1 (1.00) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL28923930 | 0.76 | CYP19A1 (0.58) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL936700 | 0.76 | CYP19A1 (0.66) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL936304 | 0.75 | CYP19A1 (0.57) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL28928582 | 0.75 | CYP19A1 (0.53) | CYP19A1NPC1RAB9AHRH4HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8568706-B2 | Modified human interferon-beta polypeptides | ALLOZYNE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-7829659-B2 | Methods of modifying polypeptides comprising non-natural amino acids | ALLOZYNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | CYP19A1 3595/4885NPC1 3938/4885RAB9A 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.